myfortic 180 mg
novartis pharma gmbh - germania - mycophenolatum - compr. gastrorez. - 180mg - imunosupresoare imunosupresoare selective
myfortic 360 mg
novartis pharma gmbh - germania - mycophenolatum - compr. gastrorez. - 360mg - imunosupresoare imunosupresoare selective
humulin m suspensie injectabila 100 ui/ml
eli lilly and company - insulinum umane - suspensie injectabila - 100 ui/ml
humulin m suspensie injectabila in cartus 100 ui/ml
lilly france s.a.s. - insulinum umane - suspensie injectabila in cartus - 100 ui/ml
humulin nph suspensie injectabila in cartus 100 ui/ml
lilly france s.a.s. - insulinum umane - suspensie injectabila in cartus - 100 ui/ml
humulin nph suspensie injectabila 100 ui/ml
eli lilly and company - insulinum umane - suspensie injectabila - 100 ui/ml
mixtard 30 hm 100 ui/ml suspensie injectabilă
novo nordisk a/s - insulinum umane - suspensie injectabilă - 100 ui/ml
myfortic 180 mg comprimate gastrorezistente
novartis pharma ag - acid mycophenolicum - comprimate gastrorezistente - 180 mg
protafan hm 100 ui/ml suspensie injectabilă
novo nordisk a/s - insulinum umane - suspensie injectabilă - 100 ui/ml
nulojix
bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - imunosupresoare - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.